,TLR4

Chi Zhang1,2, Marina Simón1,2, Jeffrey M Harder3

  • 1Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.

Scientific reports
|May 15, 2025
PubMed
概括

收费类受体4 (TLR4) 似乎没有在慢性青光瘤的发展中发挥作用. 在小鼠模型上的研究表明,在缺乏TLR4的小鼠中,青光眼的进展没有显著差异,这表明它不是一个可行的治疗点.